SeaStar Medical Holding Corporation
SeaStar Medical Holding Corporation (ICU) Stock Overview
Explore SeaStar Medical Holding Corporation’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
7.8M
P/E Ratio
-0.26
EPS (TTM)
$-2.34
ROE
6.02%
ICU Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of SeaStar Medical Holding Corporation (ICU) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $1465176.51.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.26 and a market capitalization of 7.8M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Analyst Recommendations
Price Targets
Company Profile
SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.
Eric Schlorff
19
3513 Brighton Boulevard, Denver, CO
2021